scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1111/J.1365-2516.2006.01196.X |
P698 | PubMed publication ID | 16445813 |
P2093 | author name string | G Dolan | |
P2860 | cites work | Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient | Q34339769 |
Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation | Q43627159 | ||
New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation | Q45884605 | ||
GUIDELINES ON THERAPEUTIC PRODUCTS TO TREAT HAEMOPHILIA AND OTHER HEREDITARY COAGULATION DISORDERS. | Q45886952 | ||
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. | Q51037857 | ||
P921 | main subject | emerging pathogen | Q108429945 |
Creutzfeldt-Jakob disease | Q49989 | ||
hemophilia | Q134003 | ||
P304 | page(s) | 16-20; discussion 26-8 | |
P577 | publication date | 2006-03-01 | |
P1433 | published in | Haemophilia | Q15753375 |
P1476 | title | Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience | |
P478 | volume | 12 Suppl 1 |
Q37303186 | Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A |
Q36488803 | Blood safety and the choice of anti-hemophilic factor concentrate |
Q37234113 | Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells |
Q36638892 | Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK? |
Q24235721 | Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically) |
Q24242392 | Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) through medical treatment (iatrogenically) |
Q38527508 | Recombinant activated factor VII: 30 years of research and innovation |
Search more.